But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...

Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $70 from $80 and keeps an Overweight rating on the shares. The ...

Chardan raised the firm’s price target on Intellia Therapeutics (NTLA) to $91 from $88 and keeps a Buy rating on the shares. The company ...

Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.

Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.

Intellia Therapeutics (NASDAQ: NTLA) announced some positive new clinical trial data only to see its stock slide by 18% -- ...

In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...

Cash runway is not expected to get Intellia to meaningful data readouts for their Phase III trials. See why NTLA stock is a ...

Intellia Therapeutics' NTLA-2002 Phase II results last month were underwhelming, however, management reassured investors on ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.